BLUE Quote, Financials, Valuation and Earnings

Arcturus Therapeutics Holdings has a net margin of -573.01% compared to bluebird bio's net margin of -142.88%. bluebird bio's return on equity of -245.94% beat Arcturus Therapeutics Holdings's return on equity of -31.04%.

bluebird bio has a consensus price target of $23.25, signalling upside risk potential of 276.62%. On the other hand Arcturus Therapeutics Holdings has an analysts' consensus of $73.10 which suggests that it could grow by 472.44%. Given that Arcturus Therapeutics Holdings has higher upside potential than bluebird bio, analysts believe Arcturus Therapeutics Holdings is more attractive than bluebird bio.

bluebird bio has a beta of 0.785, which suggesting that the stock is 21.477% less volatile than S&P 500. In comparison Arcturus Therapeutics Holdings has a beta of 2.962, suggesting its more volatile than the S&P 500 by 196.207%.

bluebird bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Arcturus Therapeutics Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. bluebird bio pays -- of its earnings as a dividend. Arcturus Therapeutics Holdings pays out -- of its earnings as a dividend.

bluebird bio quarterly revenues are $10.6M, which are smaller than Arcturus Therapeutics Holdings quarterly revenues of $21M. bluebird bio's net income of -$60.8M is lower than Arcturus Therapeutics Holdings's net income of -$30M. Notably, bluebird bio's price-to-earnings ratio is -- while Arcturus Therapeutics Holdings's PE ratio is 8.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for bluebird bio is 0.63x versus 2.49x for Arcturus Therapeutics Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Neurocrine Biosciences has a net margin of -573.01% compared to bluebird bio's net margin of 16.43%. bluebird bio's return on equity of -245.94% beat Neurocrine Biosciences's return on equity of 13.72%.

bluebird bio has a consensus price target of $23.25, signalling upside risk potential of 276.62%. On the other hand Neurocrine Biosciences has an analysts' consensus of $164.41 which suggests that it could grow by 41.48%. Given that bluebird bio has higher upside potential than Neurocrine Biosciences, analysts believe bluebird bio is more attractive than Neurocrine Biosciences.

bluebird bio has a beta of 0.785, which suggesting that the stock is 21.477% less volatile than S&P 500. In comparison Neurocrine Biosciences has a beta of 0.353, suggesting its less volatile than the S&P 500 by 64.731%.

bluebird bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Neurocrine Biosciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. bluebird bio pays -- of its earnings as a dividend. Neurocrine Biosciences pays out -- of its earnings as a dividend.

bluebird bio quarterly revenues are $10.6M, which are smaller than Neurocrine Biosciences quarterly revenues of $627.7M. bluebird bio's net income of -$60.8M is lower than Neurocrine Biosciences's net income of $103.1M. Notably, bluebird bio's price-to-earnings ratio is -- while Neurocrine Biosciences's PE ratio is 35.31x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for bluebird bio is 0.63x versus 5.11x for Neurocrine Biosciences. Usually stocks with elevated PS ratios are considered overvalued.

Protalix BioTherapeutics has a net margin of -573.01% compared to bluebird bio's net margin of 35.65%. bluebird bio's return on equity of -245.94% beat Protalix BioTherapeutics's return on equity of 8.75%.

bluebird bio has a consensus price target of $23.25, signalling upside risk potential of 276.62%. On the other hand Protalix BioTherapeutics has an analysts' consensus of $14.50 which suggests that it could grow by 473.12%. Given that Protalix BioTherapeutics has higher upside potential than bluebird bio, analysts believe Protalix BioTherapeutics is more attractive than bluebird bio.

bluebird bio has a beta of 0.785, which suggesting that the stock is 21.477% less volatile than S&P 500. In comparison Protalix BioTherapeutics has a beta of 0.724, suggesting its less volatile than the S&P 500 by 27.611%.

bluebird bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix BioTherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. bluebird bio pays -- of its earnings as a dividend. Protalix BioTherapeutics pays out -- of its earnings as a dividend.

bluebird bio quarterly revenues are $10.6M, which are smaller than Protalix BioTherapeutics quarterly revenues of $18.2M. bluebird bio's net income of -$60.8M is lower than Protalix BioTherapeutics's net income of $6.5M. Notably, bluebird bio's price-to-earnings ratio is -- while Protalix BioTherapeutics's PE ratio is 84.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for bluebird bio is 0.63x versus 3.93x for Protalix BioTherapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Sangamo Therapeutics has a net margin of -573.01% compared to bluebird bio's net margin of -309.84%. bluebird bio's return on equity of -245.94% beat Sangamo Therapeutics's return on equity of -217.48%.

bluebird bio has a consensus price target of $23.25, signalling upside risk potential of 276.62%. On the other hand Sangamo Therapeutics has an analysts' consensus of $5.00 which suggests that it could grow by 495.81%. Given that Sangamo Therapeutics has higher upside potential than bluebird bio, analysts believe Sangamo Therapeutics is more attractive than bluebird bio.

bluebird bio has a beta of 0.785, which suggesting that the stock is 21.477% less volatile than S&P 500. In comparison Sangamo Therapeutics has a beta of 1.494, suggesting its more volatile than the S&P 500 by 49.44%.

bluebird bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sangamo Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. bluebird bio pays -- of its earnings as a dividend. Sangamo Therapeutics pays out -- of its earnings as a dividend.

bluebird bio quarterly revenues are $10.6M, which are larger than Sangamo Therapeutics quarterly revenues of $7.6M. bluebird bio's net income of -$60.8M is lower than Sangamo Therapeutics's net income of -$23.4M. Notably, bluebird bio's price-to-earnings ratio is -- while Sangamo Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for bluebird bio is 0.63x versus 2.94x for Sangamo Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.